Skip to main content
Premium Trial:

Request an Annual Quote

Oxford GlycoSciences Opens New US Office

NEW YORK, Feb. 7-Oxford GlycoSciences has opened a new specialty biopharmaceutical headquarters in the United States, the company said today.


The new facility is located in Bridgewater, NJ.


It will be run by Don DeGolyer, Oxford GlycoSciences' new president of global therapeutics. DeGolyer will lead the company's research into specialty biopharmaceuticals, both in the US and internationally.


The New Jersey office will house the company's commercial team, lead by vice president of global marketing Lou Ferrari.


Oxford GlycoScience's drug development focuses on treatments for fungal infections, cancer, Gaucher disease and Fabry's disease.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.